Soft Tissue Detection on MRI, Cone Beam CT and Fan Beam CT and Integration of Functional MRI

Study summary

This clinical trial studies magnetic resonance imaging (MRI), cone beam computed tomography (CT), and fan beam CT in detecting soft tissue in patients with prostate and lung cancer undergoing radiation therapy. Comparing results of diagnostic procedures done before and during radiation therapy may help doctors predict a patient's response to treatment and help plan the best treatment.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedcone-beam computed tomography and magnetic resonance imaging

Plus 1 other study approaches.

Who it may be forLung Cancer · Prostate Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 7, 2018 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Virginia Commonwealth University

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: Virginia Commonwealth University
Interventions being studied: Radiation: cone-beam computed tomography; Radiation: magnetic resonance imaging; Radiation: computed tomography

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Radiation therapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Patients with lung cancer visible on CT who are scheduled to receive radiation treatment to the area of the primary tumor will be eligible for this study - Renal function tests (blood urea nitrogen \[BUN\], creatinine \[Cr\], glomerular filtration rate \[GFR\]) within 30 days of MRI with GFR \> 59 mL/min
All patients must give written informed consent on a form that includes Health Insurance Portability and Accountability Act (HIPAA) authorization; patient therapy will not be directed by enrollment in this study; participation in this study will not preclude patient participation in additional therapy protocols; subjects will all be recruited from patients undergoing radiotherapy at one of the Virginia Commonwealth University (VCU)-affiliated radiotherapy clinics

Reasons someone may not be able to joinExclusion criteria

Patients requiring continuous supplemental oxygen
Patients with metal implants including pace makers and defibrillators
Patients with cerebral aneurysm clips or middle ear implant
Patients with pain pump, a programmable shunt, or non-surgical metal (i.e. a foreign body)
Claustrophobic patients
Prior radiotherapy to body area under investigation
No vulnerable populations will be enrolled (prisoners, children, pregnant females, or institutionalized individuals); women of childbearing potential will undergo a pregnancy test

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Virginia Commonwealth University/Massey Cancer CenterRichmond, Virginia

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 7, 2018. Always confirm current availability with the study team.

View original record ↗